OSLO CANCER CLUSTER TODAY

- Radium Cancer Hospital
- Institute for Cancer Research
- Digital Pathology / Cancer genomics
- National Cancer Registry
- Oslo Cancer Cluster Incubator
- Ullern School
HISTORY AND FUTURE

- Norwegian Radium Hospital 1932
- Norwegian Cancer Registry 1952
- Institute for Cancer Research 1953
- Norwegian Radium Hospital Research Foundation 1986
- Oslo Cancer Cluster 2006
- Norwegian Center of Excellence (NCE) status for OCC 2007
- Oslo Cancer Cluster Innovation Park & Incubator 2015
- Oslo Cancer Cluster Innovation Park (new) 2020?
- OUS Radiumhospital cancer hospital (new) 2023+
CLUSTER COVERING THE VALUE CHAIN
INTERNATIONAL ATTRACTIVENESS

- World leading researchers (meetings and conferences, eg Cancer Crosslinks)
- Co-localisation of private companies and public research
BEST INNOVATION CLUSTER 2017 (SIVA)

• Utilize world class research, biobanks and registries

• Set up biotechs by offering infrastructure, funding and competence

• Grow companies buy offering mentoring and partnering
## GROWING INTERNATIONAL INDUSTRY

<table>
<thead>
<tr>
<th>Discovery</th>
<th>Preclinical</th>
<th>Phase I</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Market</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Companies:***
- APIM Therapeutics
- BTO
- Arctic Pharma
- zelluna IMMUNOTHERAPY
- Pretect
- inven2
- Nextera
- BerGenBio
- Nordic Nanovector
- Algeta
- PhoToCure
- Centre for Cancer Biomedicine
- OncoInvent as
- Vaccibody
- PCI Biotech
- OncoImmunity
- Lytix Biopharma
- CAST
- Balter Medical
- Ultimovacs
- Phoenix Solutions
- NTNU
- Targovax
- MyHere

---

*Discovery* - *Preclinical* - *Phase I* - *Phase 2* - *Phase 3* - *Market*
WE EDUCATE TOMORROWS ENTREPRENEURS AT ULLERN HIGH SCHOOL
IMMUNOTHERAPY – THE FOURTH LEG IN CANCER TREATMENT

Zelluna Immunotherapy AS develops T-cell receptor (TCR) therapies targeting cancer antigens. The company was founded in 2016 and is based in Oslo, Norway.

Spin-off from Radium hospital cancer research, funded and established by Incubator innovation environment.

https://youtu.be/k41b40XYbXw
Bayer AG agreed to buy Algeta ASA, its partner on the prostate-cancer medicine Xofigo, for about 17.6 billion kroner ($2.9 billion)

Bayer celebrated as one of top 3 export companies in Norway 2017
WE HAVE UNIQUE HEALTH DATA

- One health provider and lifetime individual ID numbers
- Little population mobility
- National clinical annotated biobanks
- Cancer register and biobanks

The Nordics are positioned to be a global testbed for personalized medicine
...FACILITATE EXITING US PROJECTS
Thermo Fisher Scientific receives the Norwegian Research Council Innovation award 2017 for improved analysis of the human genome that will lead to better cancer diagnostics and treatment.
...EU FUNDING – PERMIDES; 45MNOK TO COMBINE ICT/BIOtech
«Helseindustrien er en næring med dobbel gevinst – fremskrittene som gjøres bidrar til velferd og helse samtidig som skaper verdier og arbeidsplasser.

Viktig for omstillingen – flere bein å stå på.»

Statsminister Erna Solberg, åpningstale Oslo Cancer Cluster Innovasjonspark, 24. august 2015
Facilitate public/private collaboration to promote new technology and innovation (e.g. new innovation facility and Radiumhospital)